Navigation Links
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Date:5/11/2009

BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

"We are extremely pleased to add Oforta to our existing oncology portfolio, and believe it represents an exciting opportunity for sanofi-aventis U.S.," said John Harrington, Vice President and Head of the Oncology Business Unit at sanofi-aventis U.S. "Sanofi-aventis is a company committed to identifying and exploring new treatment options for patients facing serious diseases, such as CLL. This agreement further supports our efforts to help patients and complements our strong heritage of providing therapies to treat cancer."

Antisoma currently licenses certain rights and purchases Oforta from Bayer Schering Pharma AG. As part of this transaction, sanofi-aventis U.S. will acquire these agreements.

Oforta is a nucleoside analogue designed to prevent cancer cells from dividing by inhibiting DNA synthesis. Oforta was granted accelerated review and later received approval from the U.S. Food and Drug Administration (FDA) in December 2008 to treat adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Oforta is an orally administered tablet formulation of fludarabine phosphate.

About Oforta

Oforta is indicated as a single agent for the treatment of adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical b
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
2. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
3. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
6. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
8. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
9. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
10. Sigma-Aldrich Acquires Sigal Ltda and Expands Operations in Chile
11. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...,, TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Mic...day that it has re-filed the Form 52-109F1 Certifi...ief Executive Officer and James Long, the Chief Fi...ed January 12, 2009 in connection with the annual ...ptember 30, 2008. ,, The Company initially file...
(Date:11/6/2009)...,, VIENNA, Austria, November 6 /PRNewswire/...omizing, manufacturing, and marketing enzymes for ...entered into a research,agreement with Bio Sidus, ...rica. , The agreement gives EUCODIS Biosc... of interest - to Bio Sidus, proprietary collectio...
(Date:11/6/2009)...,, HAYWARD, Calif., Nov. 6 Inta...s today on its ITCA 650 (DUROS® continuous de...type 2 diabetes at the Ninth Annual Diabetes Techn...http://www.newscom.com/cgi-bin/prnh/20050301/SFTU1...of Exenatide Via ITCA 650 Lowers Plasma Glucose, H...
(Date:11/5/2009)...,, WELLINGTON, Colo., Nov. 5 Th...dog towns in the western U.S. This rare carnivore...y susceptible to plague and often entire populatio...ldlife Service (FWS) has implemented a ferret bree...ve ferrets into their formerly native habitat. Un...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
...March 11 Haemonetics,Corporation announced today ...d position of Chief Marketing Officer. In this pos...obal marketing of Haemonetics, full,product portfo... President,Donor Division., Brian Concannon, Chie...,architect of our strategic vision to be the globa...
...1 Supelco, a division of,Sigma-Aldrich (Nasdaq: ...line, a family of innovative high-purity liquid ch...e analysis speed and resolving power of,sub-2-micr...scentis Express,HILIC can perform high-speed and h..., "The retention of highly polar compounds such a...
...everage DMetrix,s high-throughput array microscope...dosimetry, TUCSON, Ariz., March 11 DMetrix, Inc....athology systems, the Uniformed,Services Universit...search,Institute (AFRRI), and the Henry M. Jackson...ne (HJF) announced today that they have entered in...
Other Biology Technology:Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer 2Supelco(R) Introduces Ascentis(R) Express HILIC HPLC Columns for High-Speed and High-Efficiency Separations 2DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement 2DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement 3
(Date:11/4/2009)...s., Oct. 20 Aware, Inc. ...technology and biometrics software, today reported...ptember 30, 2009. ,, Michael Tzannes, Aware,s...ier today, we announced an agreement to sell our D...new fabless semiconductor company being spun out o...
(Date:11/4/2009)...LL Scientists at the University of North Carolina...ity of California, San Francisco have developed an... target diseases for existing drugs. , The resea...res how similar the structures of all known drugs ... known as ligands -- of disease targets within the...
(Date:11/3/2009)...may be the ultimate loner of the ocean, cruising t...f researchers has discovered that the sharks have ...that over tens of thousands of years the white sha...ed themselves into a population genetically distin...sharks are a large, highly mobile species," said S...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Study points to new uses, unexpected side effects of already existing drugs 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 1Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 2Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 3Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 4CBC Announces Its Cosmetic Bootcamp University Program is Sold Out for New York 57011 1Elkan Gamzu Ph D Joins Hygeia Therapeutics Board of Directors as Chair 14014 1Elkan Gamzu Ph D Joins Hygeia Therapeutics Board of Directors as Chair 14014 2
...f hearing have found an underlying molecular cause...tion between deafness and the organization of liqu.... , Within the cochlea of the inner ear, sound wav...brations stimulate hair cells, which then trigger ... , Researchers have now learned that mutations in...
...llaboration with colleagues from UC Berkeley and S... has designed a novel pulsed microjet system engin...ut the pain or bruising that deeper penetration in...online today in the Proceedings of the National Ac...free drug delivery systems is driven by a combinat...
...University of Georgia scientists suggests that cur...do little ?if anything ?to reduce rates of antibio...threaten human health. , Dr. Margie Lee, professo...er colleagues have found that chickens raised on a...ristine laboratory conditions have high levels of ...
Other Biology News:Scientists identify molecular cause for one form of deafness 2Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2Study finds antibiotic resistance in poultry even when antibiotics were not used 2Study finds antibiotic resistance in poultry even when antibiotics were not used 3
Chicken Anti-Ras-related C3 botulinum toxin substrate 1 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Mouse Anti-HNF-1 Monoclonal Antibody, Unconjugated, Clone 2 from BD Biosciences Pharmingen
Rat Anti-p19ARF Monoclonal Antibody, Unconjugated, Clone 5-C3-1 from Upstate
EDG-1 Western blot control from Exalpha Biologicals, Inc.
Biology Products: